Immunome Inc

NASDAQ:IMNMUnited States

Immunome, Inc. is a biotechnology company engaged in developing targeted cancer therapies. The Company's portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, radioligand therapies and Antibody-Drug Conjugates (ADCs). Its memory B cell hybridoma technology allows for the screening and functional characterization of novel antibodies and targets. Its programs include Oncology (IMM-ONC-01), LU FAP, and SARS-CoV-2 (IMM-BCP-01). The oncology program is an antibody (IMM-ONC-01) against interleukin-38 (IL-38) a novel immune modulator for the treatment of various solid tumors. Its Targeted Effector platform uses small molecule ligands to selectively deliver drug payloads to diseased cells. It also operates AL102 and related drug candidate AL101. AL102 is an investigational small molecule gamma secretase inhibitor being evaluated in the Phase III for the treatment of desmoid tumors. AL102 is a potential once-daily oral treatment for desmoid tumors.

Contact Information

Headquarters

18702 N. CREEK PARKWAY, SUITE 100BOTHELL, WA, United States 98011

Phone

610-321-3700

Fax

302-655-5049

Executives

Chairman of the Board, President, Chief Executive Officer

Clay Siegall

Chief Financial Officer, Executive Vice President - Operations, Principal Accounting Officer, Principal Financial officer

Max Rosett

Chief Technical Officer

Phil Tsai

Chief Scientific Officer

Jack Higgins

Chief Legal Officer, General Counsel, Company Secretary

Sandra Stoneman